Key result
T2D is associated with up to 4 times higher lower limb arterial disease prevalence.
This review highlights the importance of intensive risk factor management, antiplatelet therapy, and lifestyle modifications in patients with lower extremity arterial disease.
Answers are grounded in this paper and cite their sources.
Underscores high European burden in diabetes; leaves open optimal management strategies.
Lower Limbs Arterial Disease (LEAD) affects over 40 million people in Europe and appears to be 2-4 times more prevalent in people with type 2 diabetes (PWT2D) than in the general population. LEAD patients need intensive prevention and management of risk factors. Cigarette smoking is one of the most important risk factors for peripheral arterial disease as well as hyperlipoproteinemia and hypertension. Diabetic metabolic disorders are the most important risk factors for LEAD progression. The antiplatelet drugs represent one of the basic options for the management of patients with various atherosclerotic diseases. Aspirin is the oldest and most often prescribed antiplatelet drug. Lifestyle management remains the cornerstones of LEAD patients management.
No takes yet. Share an insight, caveat, or question.
Pier Luigi Antignani (2023) conducted a review in Lower Limbs Arterial Disease (LEAD). Lower Limbs Arterial Disease affects over 40 million people in Europe and is 2-4 times more prevalent in people with type 2 diabetes, requiring intensive risk factor and lifestyle management.
Synapse has enriched 10 related papers. Consider them for comparative context: